Onco Actu du 2 mars 2017

	2.11 Etiologie - Alimentation
Poor Adolescent and Early Adulthood Diet Associated With Increased Risk for Premenopausal Breast Cancer [AACR] For this study, Michels and colleagues used data from 45,204 women enrolled in the Nurses’ Health Study II who had completed a food frequency questionnaire in 1998, when they were ages 33–52, about their diet during high school.
	2.7 Etiologie - Obésité
Wide range of cancers now linked to being overweight [NHS Choices] While the findings of this study may be worrying, it's important to focus on the positives. Losing any excess weight should help reduce your risk of developing these types of cancer, as well as other chronic diseases like heart disease and type 2 diabetes.
	4. Dépistage, diagnostic et pronostic
Novel Calculator More Easily Identifies Patients Who Will Benefit From Neoadjuvant Chemoradiation [Roswell Park Cancer Institute] Roswell Park scientists create model to inform treatment decisions for esophageal cancer.
Two migration proteins boost predictive value of pancreatic cancer biomarker [MD Anderson Cancer Center] Combination of blood markers improves detection in three cohorts of case and control samples.
	4.12 Biopsies liquides
Grail reels in $900M to bankroll large-scale cancer-screening trials [FierceBiotech] The funding will support the development and validation of blood tests, including the Circulating Cell-free Genome Atlas study, which will profile cell-free DNA in healthy people and individuals with cancer. It will also bankroll large-scale clinical trials that the company said will enroll hundreds of thousands of patients.
Drugmakers, Amazon Back Grail’s Big Cancer Trials With $900M [Xconomy] Grail needs the huge war chest to fund an exceedingly difficult quest. It is conducting large, long trials to test the worth of a blood test meant to catch cancer when it’s most treatable—long before patients show any symptoms—by detecting fragments of cancer DNA shed by tumors.
Bristol-Myers Squibb Expands Focus on Precision Medicine with Investment and Planned Collaboration with GRAIL on Blood-Based Cancer Screening [BMS] As an investor, Bristol-Myers Squibb will gain early access to GRAIL’s comprehensive clinical trial databases that may serve as a rich resource for understanding tumor genomics.
GRAIL Closes Over $900 Million Initial Investment in Series B Financing to Develop Blood Tests to Detect Cancer Early [GRAIL] GRAIL will use the proceeds of the financing for continued product development and validation of blood tests for early-stage cancer detection, including the previously announced Circulating Cell-free Genome Atlas (CCGA) study and other large-scale clinical trials that are expected to enroll hundreds of thousands of patients.
	5. Traitements
Increased survival with new treatment for aggressive form of childhood cancer [Karolinska Institutet] In all, 1347 children from 18 countries were included in a so called phase 3 study, of which 598 children were randomised to be treated with busulfan-melphalan or standard therapy.
Thwarting Deadly Diseases Before They Start: The New Science of Cancer Interception [Johnson & Johnson] The theory behind interception is that finding these pre-malignant cells, and targeting them, will give us the best shot at possibly curing cancer.
	5.10 Traitements - Essais
Sanofi Launches Digital Clinical Trials to Improve Recruitment and Reduce Trial Times [Sanofi] Using digital technologies to streamline finding and retaining participants for the entire length of a study has the potential to reduce the time required for a typical trial by at least 30%, according Science 37.
	5.12.2 Immunothérapies - CAR-T
After Trial Deaths, Juno Pivots and Scraps Lead CAR-T Therapy [Xconomy] “Until the picture is complete, it’s wrong to isolate any variable,” Bishop said at the time. The picture still remains unclear. In a statement this afternoon, Juno said it identified “multiple factors” that could have contributed to the problem, from the chemotherapy to the product itself.
Juno pulls the plug on a once-promising cancer treatment [STAT] DLBCL is the most common form of non-Hodgkin lymphoma, and CAR-T therapies, which would treat patients whose cancer endured standard treatment, present a blockbuster opportunity. Kite’s DLBCL treatment is in line for peak sales of $1.5 billion a year, according to Cowen analyst Eric Schmidt.
Months after another lethal setback, Juno finally opts to kill lead CAR-T [EndPoints] Shares of Juno dropped 8% Wednesday evening on the biotech’s reminder of its seriously flawed efforts.
Juno ends development of high-profile leukemia drug after deaths [Reuters] Juno said its internal investigation identified multiple factors that increased the risk of severe toxic reactions, including "factors related to the product."
	5.2 Pharma
Celgene, Agios gain FDA speedy review for AML med enasidenib [FierceBiotech] Celgene is also looking at enasidenib compared with conventional therapy in older patients, again with an IDH2 mutation and relapsed or refractory AML, in an ongoing phase 3 test.
FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation [Celgene] The NDA submission is based on results from AG221-C-001, a single-arm phase I/II study of enasidenib in patients with advanced hematologic malignancies with an IDH2 mutation. Early data from the relapsed or refractory AML patients in this study were presented at the 2015 American Society of Hematology (ASH) Annual Meeting.
Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin® and Chemotherapy [Genentech] Full results from the APHINITY trial will be presented at an upcoming medical meeting in 2017.
Celgene, Agios beat a short path to an FDA decision on AML drug [EndPoints] This is Agios’ lead drug, and it arrived at the FDA swiftly, by biotech standards. But CEO David Schenkein doesn’t think about drug development in traditional terms.
Roche says drug combo cuts breast cancer deaths in key trial [Reuters] Roche said on Thursday that combing its Perjeta and Herceptin drugs with chemotherapy reduced recurrence of aggressive breast cancer or death compared to Herceptin and chemo, an important trial outcome seen helping shield the Swiss drugmaker's oncology franchise from cheaper copies.
	5.3.4 Traitements - AMM (FDA, EMA)
FDA Approves Nivolumab for Bladder Cancer [NCI] This study of nivolumab has some limitations, Dr. Apolo noted. For example, because it was a single-arm study, the efficacy of nivolumab was not compared directly with that of another treatment. In addition, the accelerated approval was based on the objective response rate, the study’s surrogate endpoint.
	5.4 Traitements - Economie
NICE shoots down Merck's Keytruda in first-line NSCLC—and the med won't be getting any CDF love, either [FiercePharma] It’s a roadblock for Merck, which has been pushing full steam ahead with Keytruda, capturing a critical lead over Bristol-Myers Squibb nemesis Opdivo in the process.
NICE says patients accessing more cancer drugs following price drops [NICE] Patients will have routine access to more cancer drugs as companies have dropped their prices as part of the reformed Cancer Drugs Fund (CDF) process.
	5.9 AACR
Welcome to the AACR Annual Meeting 2017 Online Itinerary Planner [AACR] This site allows you to browse and search all of the sessions and presentations at the AACR Annual Meeting 2017, April 1-5, Washington, DC.
	5.9.8 AACR - Pharma
ImmunoGen Announces Presentations at AACR Annual Meeting [ImmunoGen] he presentations at AACR cover a wide-array of antibody-drug conjugates (ADCs) innovations, including further advancements to linkers and payloads and novel targets for both solid tumors and hematological malignancies.
NewLink Genetics Announces Presentation of Two Abstracts at AACR [NewLink Genetics] Interim Phase 2 Clinical Results of IDO Pathway Inhibitor, Indoximod Selected for an Oral Presentation During the Clinical Trial Plenary Session.
Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017 [BMS] Results will be disclosed for Opdivo (nivolumab), as a single-agent and in combination with Yervoy (ipilimumab), as well as an investigational, optimized, once-daily IDO1 inhibitor alone or in combination with Opdivo.
	6.1 Observation
Colorectal Cancer Statistics, 2017 [ACS] Despite dramatic drops in overall incidence and mortality, striking disparities remain.
	6.10.1 Politiques (USA)
Would Trump's FDA Deregulation Create An Age Of Miracles? Don't Bet On It [Forbes] One idea that should be dismissed: that lowering the bar for drug approvals will make medicines cheaper if other changes aren't made to the health care system.
	6.11 Patients
People who are dying should be asked about their spiritual beliefs, says NICE [NICE] NICE has published new guidance calling on healthcare professionals to ask adults in the final days of life about their religious or spiritual beliefs.
	6.3 Associations/Fondations
Patient advocacy groups have close ties with industry, but some lack transparency [STAT] Notably, of the 104 organizations they looked at, 13 didn’t name their donors either on their website or in their annual report. And only a handful list the exact contribution amounts.
More Than 80 Percent of Patient Groups Accept Drug Industry Funds, Study Shows [NY Times] For some groups, the donations from industry accounted for more than half of their annual income, and in nearly 40 percent of cases, industry executives sit on governing boards, according to the study, which is published in The New England Journal of Medicine.